Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > International preclinical project Managet

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Jun 29, 2021 4:08pm

123 Views

Post# 33467649

RE:International preclinical project Managet

How much longer can SORT1+ fly in stealth mode completely under the radar of all these supposed bleeding edge cancer experts?

scarlet1967 wrote:

I didn't see that coming!?

Check out this job at Theratechnologies Inc.: Preclinical Project Manager | Chef de projets prcliniques
https://www.linkedin.com/jobs/view/2621389599